<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2718">
  <stage>Registered</stage>
  <submitdate>26/03/2010</submitdate>
  <approvaldate>26/03/2010</approvaldate>
  <nctid>NCT01094769</nctid>
  <trial_identification>
    <studytitle>Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease</studytitle>
    <scientifictitle>Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>58667</secondaryid>
    <secondaryid>2010/10</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Nephropathies</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Moxonidine
Treatment: drugs - Placebo

Experimental: Moxonidine - 

Placebo Comparator: Placebo - 


Treatment: drugs: Moxonidine
Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.

Treatment: drugs: Placebo
lactose capsule taken once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Urine albumin/creatinine ratio (UACR) - The primary outcome measure is the difference in the change of UACR between active treatment and placebo from baseline to week 12 of treatment.</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>muscle sympathetic nerve activity (MSNA) - Secondary outcome measure is the difference between active and placebo treatment in the change from baseline to week 12 of treatment in muscle sympathetic nerve activity</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  age: 18-75 years

          -  diabetic nephropathy as defined by the mean of three consecutive early morning urinary
             albumin-creatinine ratios (UACR) of &gt;300mg per gram, or &gt; 200mg per gram in patients
             receiving therapy targeted at blockade of the RAS</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  non-diabetic kidney disease

          -  UACR of more than 3500mg per gram, an estimated glomerular filtration rate of less
             than 30ml/min/1.73m2.

          -  chronic urinary tract infection.

          -  severe hypertension

          -  heart failure NYHA class II-IV

          -  major cardiovascular disease within the previous 6 months

          -  left ventricular ejection fraction &lt;55%</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2015</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred &amp; Baker Medical Unit - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Baker IDI Heart and Diabetes Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether moxonidine is effective in reducing urine
      albumin levels in patients with diabetic kidney disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01094769</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Markus P Schlaich, MD</name>
      <address>Baker IDI Heart and Diabetes Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Markus P Schlaich, MD</name>
      <address />
      <phone>61 3 8532 1502</phone>
      <fax />
      <email>markus.schlaich@bakeridi.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>